aTyr Pharma Announces Encouraging Phase 1b/2 Results for Resolaris™ in its First Rare Myopathy Trial

Thu, Mar 31, 2016, 2:09AM EDT – US Markets open in 7 hrs and 21 mins 

aTyr Pharma Announces Encouraging Phase 1b/2 Results for Resolaris™ in its First Rare Myopathy Trial

First patient trial of a Physiocrine-based investigational new drug
Preliminary analysis shows potential activity signals in three months of treatment
Safety, tolerability, immunogenicity & PK profile supports Resolaris program advancement in FSHD and potentially other rare diseases

PR Newswire 

SAN DIEGO, March 30, 2016 /PRNewswire/ — aTyr Pharma, Inc. (LIFE) a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced results from a Phase 1b/2 clinical trial evaluating Resolaris in adult FSHD (facioscapulohumeral muscular dystrophy) patients. The Company is developing Resolaris, a potential first-in-class protein therapeutic, for the treatment of rare myopathies with an immune component (RMICs). The Phase 1b/2 study was designed to evaluate the safety, tolerability, immunogenicity and pharmacokinetic (PK) profile of Resolaris in adult FSHD patients, the Company’s first treated RMIC population. In addition, the study also evaluated the utility of exploratory pharmacodynamic (PD) markers (including MRI measurements to quantitate areas of potential muscle inflammation) and clinical assessments (including patient reported outcomes).  

“As the first clinical trial of a Physiocrine-based investigational new drug in patients, our data set provides important insights about the safety, tolerability, immunogenicity and PK profile of Resolaris in a very challenging disease setting, and explores potential PD markers and clinical assessments in FSHD,” said John Mendlein, PhD, Chief Executive Officer of aTyr. “It is our vision to provide patients with FSHD and other muscular dystrophies, such as limb-girdle muscular dystrophy (LGMD) 2B, an innovative treatment that potentially modulates immune components and other important aspects of disease progression.” 

더보기

http://finance.yahoo.com/news/atyr-pharma-announces-encouraging-phase-200200120.html?soc_src=mediacontentstory&soc_trk=tw#

Related Post

ATyr Pharma Raises $76M Round to Advance Physocrin...
views 191
ARS 전문 바이오벤쳐기업 ATyr Pharma가 7천 6백만 달러 (약 800억원)의 투자유치에 성공했다는 소식입니다. 첨부한 PDF 파일을 참조하시기 바랍니다. ...
Muscular dystrophy biotech aTyr Pharma sets terms ...
views 175
Muscular dystrophy biotech aTyr Pharma sets terms for $75 million IPO4/27/15 aTyr Pharma, which is developing restorative protein therapeutics for rar...
0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2010-2018 Medicinal Bioconvergence Research Center. All rights reserved.

Log in with your credentials

Forgot your details?

Skip to toolbar